{'fraction_non_alphanumeric': 0.019438444924406047, 'fraction_numerical': 0.008639308855291577, 'mean_word_length': 5.105263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients with relapsed or refractory diffuse large B-cell lymphoma contributing to its recent approval by the US Food and Drug Administration.